Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina

Abstract

The nonpeptide GP IIb/IIIa antagonist lamifiban protected patients with unstable angina from severe ischemic events during a 3- to 5-day infusion and reduced the incidence of death and infarction at 1 month, suggesting considerable promise for this new therapeutic approach.